Protelos (strontium ranelate), the only osteoporosis therapy to simultaneously increase bone formation and decrease bone resorption, was launched today by Servier Laboratories. The first in a new class of osteoporosis therapies called dual action bone agents (DABAs), Protelos is licenced for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fracture.
Recent Blog Post

September, 2023
Study Reveals Higher BMI Puts Adolescents at Risk for Depression
5th September 2023 – By King’s College London Children between the ages of 12 and 16 with a higher body...

August, 2023
Diversity at TwinsUK: Genevieve
Genevieve joined the department in 2010 and has since gained an extensive knowledge of the TwinsUK data. She is responsible...

August, 2023
Diversity at TwinsUK: Bridget
Bridget is one of our Clinical Research Nurses, part of the clinic team who you’ll see when coming to St...